Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allogeneic NK Cells · 1 trial · 9 indications
Dose Limiting toxicities assessed in a incrementing dose design.
| Arm | Type | Description |
|---|---|---|
| AlloNK | EXPERIMENTAL | AlloNK, dosed after a conditioning regimen, combined with Rituximab. |
| Name | Type | Description |
|---|---|---|
| Allogeneic NK Cells | DRUG | AlloNK, dosed after a conditioning regimen, combined with Rituximab. |
For Subjects with Refractory Rheumatoid Arthritis (RA): * Documented diagnosis of RA, meeting the 2010 ACR/EULAR classification criteria. * Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive. * High-sensitivity C-reactive protein (hs-CRP) \> 3 mg/L or Erythrocyte Sediment...
Top 20 of 27 competitors
Allogeneic NK Cells, also known as AlloNK, is an investigational cell therapy being studied for refractory Rheumatoid Arthritis (RA) and other B-cell dependent rheumatologic diseases, including Idiopathic Inflammatory Myopathies, Systemic Sclerosis, and Sjogren Syndrome. It is in Phase 2 clinical development and is not yet approved.
Allogeneic NK Cells is a non-genetically modified, cord blood-derived natural killer cell therapy. It is being studied in combination with rituximab, which targets B cells. The therapy is designed to work in B-cell dependent rheumatologic diseases, though the specific molecular target of the NK cells themselves is not detailed.
Allogeneic NK Cells is being developed by Artiva Biotherapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ARTV on the NASDAQ.
Allogeneic NK Cells is currently in Phase 2 clinical development. It is an investigational therapy and has not received FDA approval. The ongoing Phase 2 trial is recruiting participants to evaluate the therapy in refractory Rheumatoid Arthritis and related conditions.
Allogeneic NK Cells is being studied in a single Phase 2 clinical trial with the identifier NCT06991114. The trial is titled 'AlloNK, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.' It is currently recruiting and aims to enroll 90 participants.
Yes, Allogeneic NK Cells is also known as AlloNK. The clinical trial NCT06991114 refers to the therapy as AlloNK, an allogeneic non-genetically modified, cord blood-derived NK cell therapy. Both names refer to the same investigational cell therapy being developed by Artiva Biotherapeutics.